Rein Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Research and development | $11.0M | $14.2M | $4.0M | $18.0M | $17.0M |
| Operating expenses | $50.6M | $65.1M | $16.3M | $27.6M | $26.6M |
| Operating income | -$50.6M | -$65.1M | -$16.3M | -$27.6M | -$26.6M |
| Income tax expense | -$712,000 | -$1.5M | $0 | $0 | $0 |
| Net income | -$49.9M | -$62.9M | -$15.7M | -$27.3M | -$26.2M |
| Balance Sheet | |||||
| Cash and equivalents | $3.2M | $12.9M | $17.3M | $5.2M | $3.6M |
| Current assets | $4.3M | $13.7M | $18.3M | $21.9M | $48.2M |
| Total assets | $24.2M | $62.2M | $106.0M | $22.0M | $48.5M |
| Current liabilities | $6.2M | $5.7M | $4.4M | $3.4M | $4.5M |
| Total liabilities | $7.2M | $7.8M | $7.7M | $3.4M | $4.6M |
| Stockholders' equity | $16.9M | $54.4M | $98.3M | $18.6M | $43.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$19.4M | -$22.3M | -$19.8M | -$24.9M | -$23.8M |
| Depreciation and amortization | $1,000 | $63,000 | $119,000 | $169,000 | $121,000 |
| Stock-based compensation | $2.2M | $1.1M | $1.2M | $2.1M | $2.3M |
| Capital expenditure | — | — | — | — | $157,000 |
| Free cash flow | — | — | — | — | -$23.9M |
| Impairments | $0 | $0 | $0 | — | — |
Shares outstanding 85.5M · Free float 92.0%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.